In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (KPTI), with a price target of $32. The company’s shares closed last Monday at $11.03.
According to TipRanks.com, White is a 5-star analyst with an average return of 17.6% and a 51.8% success rate. White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Inc., Syndax Pharmaceuticals Inc, and Aeglea Biotherapeutics Inc.
Currently, the analyst consensus on Karyopharm Therapeutics is a Strong Buy with an average price target of $20.17.
See today’s analyst top recommended stocks >>
Based on Karyopharm Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $43.42 million. In comparison, last year the company had a GAAP net loss of $33.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.
